Amiodarone Use and All-Cause Mortality in Patients With a Continuous-Flow Left Ventricular Assist Device

Rakesh Gopinathannair, Naga Venkata K. Pothineni, Jaimin R. Trivedi, Henri Roukoz, Jennifer Cowger, Mustafa M. Ahmed, Adarsh Bhan, Ashwin K. Ravichandran, Geetha Bhat, Amin Al Ahmad, Andrea Natale, Luigi Di Biase, Mark S. Slaughter, Dhanunjaya Lakkireddy

Research output: Contribution to journalArticlepeer-review

6 Scopus citations


BACKGROUND: Atrial and ventricular arrhythmias are commonly encountered in patients with advanced heart failure, with amiodarone being the most commonly used antiarrhythmic drug in continuous-flow left ventricular assist device (CF-LVAD) recipients. The purpose of this study was to assess the impact of amiodarone use on long-term all-cause mortality in ptients with a CF-LVAD. METHODS AND RESULTS: A retrospective multicenter study of CF-LVAD was conducted at 5 centers including all CF-LVAD implants from 2007 to 2015. Patients were stratified based on pre–CF-LVAD implant amiodarone use. Additional use of ami-odarone after CF-LVAD implantation was also evaluated. Primary outcome was all-cause mortality during long-term follow-up. Kaplan-Meier curves were used to assess survival outcomes. Multivariable Cox regression was used to identify predictors of outcomes. Propensity matching was done to address baseline differences. A total of 480 patients with a CF-LVAD (aged 58±13 years, 81% men) were included. Of these, 170 (35.4%) were on chronic amiodarone therapy at the time of CF-LVAD implant, and 310 (64.6%) were not on amiodarone. Rate of all-cause mortality over the follow-up period was 32.9% in the amiodarone group compared with 29.6% in those not on amiodarone (P=0.008). Similar results were noted in the propensity-matched group (log-rank, P=0.04). On multivariable Cox regression analysis, amiodarone use at baseline was independently associated with all-cause mortality (hazard ratio, 1.68 [95% CI, 1.1–2.5]; P=0.01). CONCLUSIONS: Amiodarone use was associated with significantly increased rates of all-cause mortality in CF-LVAD recipients. Earlier interventions for arrhythmias to avoid long-term amiodarone exposure may improve long-term outcomes in CF-LVAD recipients and needs further study.

Original languageEnglish (US)
Article numbere023762
JournalJournal of the American Heart Association
Issue number11
StatePublished - Jun 7 2022

Bibliographical note

Publisher Copyright:
© 2022 The Authors. Published on behalf of the American Heart Association, Inc., by Wiley.


  • amiodarone
  • arrhythmias
  • left ventricular assist device
  • mortality

PubMed: MeSH publication types

  • Journal Article
  • Multicenter Study


Dive into the research topics of 'Amiodarone Use and All-Cause Mortality in Patients With a Continuous-Flow Left Ventricular Assist Device'. Together they form a unique fingerprint.

Cite this